H.C. Wainwright raised the firm’s price target on Revolution Medicines (RVMD) to $62 from $56 and keeps a Buy rating on the shares. The firm says RMC-9805 delivered in KRASG12D+ pancreatic cancer. It sees promise in the combination of RMC-9805 and RMC-6236.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines price target raised to $82 from $72 at Guggenheim
- Revolution Medicines price target raised to $60 from $55 at Oppenheimer
- Revolution Medicines presents initial data from RMC-9805 study
- Revolution Medicines data validates RMC-6236’s anti-tumor activity, says Wedbush
- Revolution Medicines presents data from RMC-6236 Monotherapy Study